about
Platelet-to-lymphocyte ratio but not neutrophil-to-lymphocyte ratio predicts high on-treatment platelet reactivity in clopidogrel-treated patients with acute coronary syndrome.The first six-month clinical outcomes and risk factors associated with high on-treatment platelet reactivity of clopidogrel in patients undergoing coronary interventions.Proteomic signatures of antiplatelet drugs: new approaches to exploring drug effects.Analysis of the CYP2C19 genotype associated with bleeding in Serbian STEMI patients who have undergone primary PCI and treatment with clopidogrel.
P2860
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh
2014年學術文章
@zh-hant
name
Clopidogrel resistance: the way forward.
@ar
Clopidogrel resistance: the way forward.
@de
Clopidogrel resistance: the way forward.
@en
Clopidogrel resistance: the way forward.
@fr
type
label
Clopidogrel resistance: the way forward.
@ar
Clopidogrel resistance: the way forward.
@de
Clopidogrel resistance: the way forward.
@en
Clopidogrel resistance: the way forward.
@fr
prefLabel
Clopidogrel resistance: the way forward.
@ar
Clopidogrel resistance: the way forward.
@de
Clopidogrel resistance: the way forward.
@en
Clopidogrel resistance: the way forward.
@fr
P2860
P1476
Clopidogrel resistance: the way forward.
@en
P2093
Shuvanan Ray
P2860
P304
P356
10.1016/J.IHJ.2014.08.012
P407
P577
2014-09-01T00:00:00Z